Swk Hldgs Corp Stock Price, News & Analysis

SWK Holdings Corporation (Nasdaq: SWKH) has been added to the Russell 2000, Russell 3000, and Russell MicroCap Indexes, effective June 27, 2022. This inclusion reflects the company's growth and aims to enhance shareholder value by increasing stock liquidity and awareness within the investment community. CEO Winston Black stated that the company is addressing funding needs in the life sciences sector while maintaining financial discipline. FTSE Russell, the index provider, ranks stocks based on market capitalization, and SWK's membership will last for one year, impacting future investment strategies.

Enteris BioPharma, a subsidiary of SWK Holdings (SWKH), presented two clinical studies on oral formulations of leuprolide at ENDO 2022. Results indicate that their Peptelligence^® platform delivers significant circulating drug concentrations comparable to injected formulations. The studies demonstrated successful systemic delivery of leuprolide orally, with positive pharmacokinetic profiles and effective hormonal suppression of LH, FSH, and estradiol. No severe adverse events were reported, marking a milestone in alternative treatments for conditions like endometriosis.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has published a white paper titled "Protecting Workers and the Environment: Facilities and Processes Key to Making Highly Potent Drug Products." The paper highlights the importance of specialized knowledge and facilities in manufacturing highly potent active pharmaceutical ingredients (HPAPIs). The recent renovation of Enteris' Boonton, NJ facility enhances its capabilities in HPAPI handling. Given the current shortage of U.S.-based facilities for HPAPI production, Enteris aims to address industry challenges through its advanced manufacturing capabilities.

On May 26, 2022, Enteris BioPharma engaged its employees in a charitable event, creating stuffed teddy bears for Ronald McDonald House Charities to comfort sick children. This initiative emphasized teamwork and community support, aligning with the company’s patient-focused values. The bears were distributed to families in New Brunswick, NJ, providing comfort during tough times. Enteris is a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering contract development and manufacturing services, leveraging proprietary drug delivery technologies to address unmet clinical needs.

SWK Holdings Corporation (Nasdaq: SWKH) announced a $200 million universal shelf registration statement on Form S-3 and a $10 million stock repurchase program authorized by its Board of Directors. The repurchase will be executed through a 10b5-1 trading plan until May 15, 2023. CEO Winston Black stated that these moves aim to enhance the company's financial position and support life sciences firms' capital needs. There are no guarantees regarding the completion of any debt offerings or the exact number of shares repurchased.

SWK Holdings Corporation (SWKH) reported a strong first quarter of 2022 with total revenue increasing by 18% to $11.1 million year-over-year. The company achieved a GAAP net income of $3.5 million, reflecting a 2.9% growth. The finance portfolio realized yield rose to 22.5%, indicating solid loan performance. As of March 31, 2022, tangible financing book value per share reached $18.39, a 12.7% year-over-year increase. Total investment assets decreased by 10.6% year-over-year to $195.8 million. The company is well-positioned with $63.4 million available in cash and credit facilities.

SWK Holdings Corporation (Nasdaq: SWKH) will host a conference call and audio webcast on May 11, 2022 at 10:00 a.m. ET to discuss its Q1 2022 financial results. Participants can join by dialing (844) 378-6488 for the U.S. or (412) 317-1079 for international calls, using passcode 10166330. The webcast will be available on the company's website and archived for 90 days afterward. SWK specializes in financing solutions for small to mid-sized healthcare companies and owns Enteris BioPharma, which develops innovative drug delivery technologies.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), will exhibit at CPhI North America 2022 from May 17-19 in Philadelphia. The company aims to showcase its innovative drug delivery technologies, including Peptelligence® and ProPerma®, which facilitate the oral delivery of challenging compounds. Enteris also provides comprehensive contract manufacturing services, enhancing its position in the pharmaceutical sector. CEO Rajiv Khosla emphasized the importance of this event for exploring partnerships in drug development and manufacturing.